ACP
VRNA

Acuta Capital Partners’s Verona Pharma VRNA Stock Holding History

Acuta Capital Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,000
Closed -$378K – 43
2023
Q4 		$378K Buy
+19,000
New +$281K 0.21% 34

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Acuta Capital Partners's VRNA Position: Q1 2024 in Review

Acuta Capital Partners sold out of Verona Pharma (VRNA) in Q1 2024, closing a stake of 19,000 shares — an estimated $378K sold.

Acuta Capital Partners first reported a position in VRNA in Q4 2023 and held it in 1 quarter. The position peaked at $378K in Q4 2023. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

  • Acuta Capital Partners reported no remaining Verona Pharma position as of Q1 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 19,000 Verona Pharma shares in Q1 2024, an estimated $378K.
  • Acuta Capital Partners first reported a position in Verona Pharma in Q4 2023 and held it in 1 quarter.
  • Acuta Capital Partners's Verona Pharma position peaked at $378K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.